Eli Lilly's ... comparison that masks true operational performance. What I find most compelling is the broad nature of the growth. While much attention focuses on Lilly's incretin franchise ...
In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...
ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder. ResMed makes continuous positive ...
(KFF Health News) Eli Lilly sued two medical spas for selling ... than $1 million in refunds to customers who bought Zephyr face masks, which falsely claimed to be N95-grade.
Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...
This is an audio transcript of the FT News Briefing podcast episode: ‘Trump steers the world towards a tax war’ Sonja Hutson Good morning from the Financial Times. Today is Friday, January 24th. And ...
Investor's Business Daily on MSN6d
ResMed Tumbles As Organic Sales Growth Steps Down. Will These 'Mega Trends' Save It?ResMed stock tumbled Friday after organic sales growth slowed somewhat in the second fiscal quarter. But one analyst was upbeat.
UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...
15hon MSN
Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...
Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback